Eliminating the high-risk CTV1 margin in DAHANCA oropharyngeal radiotherapy: Dosimetric impact on dysphagia and organ-at-risk doses
DOI:
https://doi.org/10.2340/1651-226X.2025.44049Keywords:
Head and neck cancer, Radiotherapy, Clinical target volume, Treatment planning, MarginAbstract
Background and purpose: Radiotherapy for head and neck cancer must balance tumour control with late toxicities such as dysphagia and xerostomia. Recent retrospective studies suggest that the margin from the gross tumour volume (GTV) to the high-dose clinical target volume (CTV1) may not be critical for local control, while larger irradiated volumes increase the risk of toxicity. The study quantifies potential reductions in dose to organs at risk (OARs) and predicted dysphagia risk when the standard 5 mm GTV-to-CTV1 margin is eliminated in oropharyngeal cancer.
Patient/material and methods: Retrospectively 30 oropharyngeal cancer patients treated consecutively during 2023 according to the DAHANCA guidelines (5 mm GTV-to-CTV1 margin) were selected. For each patient, a standard plan and a modified experimental plan (CTV1 = GTV, and CTV2 reduced by 5 mm accordingly) were generated using Pinnacle3 Auto-Planning. All plans met the DAHANCA target coverage and OAR dose constraints. Dose-volume data for relevant OARs were extracted and compared in MATLAB. Normal tissue complication probability (NTCP) model for dysphagia was applied.
Results: Margin elimination reduced high-dose CTV volumes by 70%, yielding significant dose reductions to multiple OARs. Mean doses to the upper/middle pharyngeal constrictors decreased by around 4–5 Gy
(p < 0.001) and to the contralateral submandibular gland by ~5 Gy (p < 0.001). These dosimetric gains correspond to an estimated median ΔNTCP of 6.0% of late grade ≥ 2 dysphagia. Target coverage and conformity were maintained in all plans.
Interpretation: Omitting the high-risk CTV margin can substantially reduce the dose to dysphagia-associated OAR without compromising target coverage. This approach shows promise for improving patient-reported swallowing outcomes and warrants clinical evaluation.
Downloads
References
Hutcheson KA, Lewin JS, Barringer DA, Lisec A, Gunn GB, Moore MWS, et al. Late dysphagia after radiotherapy‐based treatment of head and neck cancer. Cancer. 2012;118:5793–9.
https://doi.org/10.1002/cncr.27631 DOI: https://doi.org/10.1002/cncr.27631
Huynh T-TM, Dale E, Falk RS, Hellebust TP, Astrup GL, Malinen E, et al. Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters. Radiother Oncol. 2024;190:110044.
https://doi.org/10.1016/j.radonc.2023.110044 DOI: https://doi.org/10.1016/j.radonc.2023.110044
Nutting C, Finneran L, Roe J, Sydenham MA, Beasley M, Bhide S, et al. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, con-trolled trial. Lancet Oncol. 2023;24:868–80.
https://doi.org/10.1016/S1470-2045(23)00265-6 DOI: https://doi.org/10.1016/S1470-2045(23)00265-6
Hansen CR, Johansen J, Samsoe E, Andersen E, Petersen JBB, Jensen K, et al. Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy. Radiother Oncol. 2018;126:43–7.
https://doi.org/10.1016/j.radonc.2017.09.019 DOI: https://doi.org/10.1016/j.radonc.2017.09.019
Zukauskaite R, Hansen CR, Grau C, Samsoe E, Johansen J, Petersen JBB, et al. Local recurrences after curative IMRT for HNSCC: effect of
different GTV to high-dose CTV margins. Radiother Oncol. 2018;126:48–55.
https://doi.org/10.1016/j.radonc.2017.11.024 DOI: https://doi.org/10.1016/j.radonc.2017.11.024
Zukauskaite R, Kristensen MH, Eriksen JG, Johansen J, Samsøe E, Johnsen L, et al. Comparison of 3-year local control using DAHANCA radiotherapy guidelines before and after implementation of five millimetres geometrical GTV to high-dose CTV margin. Radiother Oncol. 2024;196:110284.
https://doi.org/10.1016/j.radonc.2024.110284 DOI: https://doi.org/10.1016/j.radonc.2024.110284
Kristensen MH, Holm AIS, Hansen CR, Zukauskaite R, Samsøe E, Maare C, et al. High-dose loco-regional pattern of failure after primary radiotherapy in p16 positive and negative head and neck squamous cell carcinoma – a DAHANCA 19 study. Clin Transl Radiat Oncol. 2024;46:100772.
https://doi.org/10.1016/j.ctro.2024.100772 DOI: https://doi.org/10.1016/j.ctro.2024.100772
Stougaard SW, Zukauskaite R, Röttger R, Lorenzen EB, Konrad ML, Nielsen CP, et al. Impact of GTV-CTV margin and other predictors on radiation-induced dysphagia in head and neck cancer patients. Acta Oncol. 2025:64.
https://doi.org/10.2340/1651-226X.2025.44021
Zukauskaite R, Eriksen J, Johansen J, Samsøe E, Kristensen MH, Johnsen L, et al. Late dysphagia after changes in high-dose CTV margins for head and neck cancer patients. Acta Oncol. 2025:64. DOI: https://doi.org/10.1016/S0167-8140(24)02012-7
https://doi.org/10.2340/1651-226X.2025.43924
Jensen K, Friborg J, Hansen CR, Samsoe E, Johansen J, Andersen M, et al. The Danish Head and Neck Cancer Group (DAHANCA) 2020 radio-therapy guidelines. Radiother Oncol. 2020;151:149–51.
https://doi.org/10.1016/j.radonc.2020.07.037 DOI: https://doi.org/10.1016/j.radonc.2020.07.037
Jensen K, Holm AIS, Eriksen JG, Skyt PS, Grau C, Bernsdorf M, et al. Danish Head and Neck Cancer Group (DAHANCA) Radiotherapy Quality Assurance Guidelines 2025. Update and new chapters: planning of complex targets, hypofractionation, planning of reirradiation, target definition after induction chemotherapy, and clarification of the guidelines for elective targets. Radiother Oncol. 2025;210:111028.
https://doi.org/10.1016/j.radonc.2025.111028 DOI: https://doi.org/10.1016/j.radonc.2025.111028
Hansen CR, Crijns W, Hussein M, Rossi L, Gallego P, Verbakel W, et al. Radiotherapy Treatment plannINg study Guidelines (RATING): a framework for setting up and reporting on scientific treatment planning studies. Radiother Oncol. 2020;153:67–78.
https://doi.org/10.1016/j.radonc.2020.09.033 DOI: https://doi.org/10.1016/j.radonc.2020.09.033
Gregoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014;110:172–81.
https://doi.org/10.1016/j.radonc.2013.10.010 DOI: https://doi.org/10.1016/j.radonc.2013.10.010
Hansen CR, Christiansen RL, Nielsen TB, Bertelsen AS, Johansen J, Brink C. Comparison of three immobilisation systems for radiation therapy in head and neck cancer. Acta Oncol. 2014;53:423–7.
https://doi.org/10.3109/0284186X.2013.813966 DOI: https://doi.org/10.3109/0284186X.2013.813966
Bertelsen A, Hansen CR, Johansen J, Brink C. Single arc volumetric modulated arc therapy of head and neck cancer. Radiother Oncol. 2010;95:142–8.
https://doi.org/10.1016/j.radonc.2010.01.011 DOI: https://doi.org/10.1016/j.radonc.2010.01.011
Van Den Bosch L, Van Der Schaaf A, Van Der Laan HP, Hoebers FJP, Wijers OB, Van Den Hoek JGM, et al. Comprehensive toxicity risk profiling in radiation therapy for head and neck cancer: a new concept for individually optimised treatment. Radiother Oncol. 2021;157:147–54.
https://doi.org/10.1016/j.radonc.2021.01.024 DOI: https://doi.org/10.1016/j.radonc.2021.01.024
Pollock AE, Arons D, Alexander GS, Alicia D, Birkman KM, Molitoris JK, et al. Gross tumor volume margin and local control in p16-positive oropharynx cancer patients treated with intensity modulated proton therapy. Head Neck. 2023;45:1088–96.
https://doi.org/10.1002/hed.27308 DOI: https://doi.org/10.1002/hed.27308
Hansen CR, Jensen K, Smulders B, Holm AIS, Samsoe E, Nielsen MS, et al. Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35. Radiother Oncol. 2023;190:109812.
https://doi.org/10.1016/j.radonc.2023.109812 DOI: https://doi.org/10.1016/j.radonc.2023.109812
Al-Mamgani A, Kessels R, Janssen T, Navran A, van Beek S, Carbaat C, et al. The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6 mm in head and neck squamous cell carcinoma: significant acute and late toxicity reduction. Radiother Oncol. 2022;168:16–22.
https://doi.org/10.1016/j.radonc.2022.01.013 DOI: https://doi.org/10.1016/j.radonc.2022.01.013
Al-Mamgani A, Kessels R, Navran A, Hamming-Vrieze O, Zuur CL, Paul de Boer J, et al. Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes. Radiother Oncol. 2021;162:170–7.
https://doi.org/10.1016/j.radonc.2021.07.016 DOI: https://doi.org/10.1016/j.radonc.2021.07.016
Zukauskaite R, Rumley CN, Hansen CR, Jameson MG, Trada Y, Johansen J, et al. Delineation uncertainties of tumour volumes on MRI of head and neck cancer patients. Clin Transl Radiat Oncol. 2022;36:121–6.
https://doi.org/10.1016/j.ctro.2022.08.005 DOI: https://doi.org/10.1016/j.ctro.2022.08.005
Nielsen M, Hansen CR, Brink C, Bertelsen AS, Kristiansen C, Jeppesen SS, et al. Efficient and accurate stereotactic radiotherapy using flattening filter free beams and HexaPOD robotic tables. J Radiosurgery SBRT. 2016;4:153–61.
Hussein M, Heijmen BJM, Verellen D, Nisbet A. Automation in intensity modulated radiotherapy treatment planning – a review of recent innovations. Br J Radiol. 2018;91:20180270.
https://doi.org/10.1259/bjr.20180270 DOI: https://doi.org/10.1259/bjr.20180270
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Christian Rønn Hansen, Anders S. Bertelsen, Irene Hazell, Sarah W Stougaard, Jørgen Johansen, Jens Overgaard, Jesper Grau Eriksen, Ruta Zukauskaite
This work is licensed under a Creative Commons Attribution 4.0 International License.
